Volume 7 Supplement 1
Synergistic effects of mifepristone on the cytotoxicity of cisplatin in cervical carcinoma cell lines and tumors grown in athymic mice
© Jurado et al; licensee BioMed Central Ltd. 2007
Published: 5 February 2007
Cisplatin and its derivatives are important drugs in cancer therapy. It has been widely used for its potent cytotoxic effects upon a variety of tumors types including cervical carcinoma. However, the administration of cisplatin is associated with serious side effects, including nephrotoxic and neurotoxic events. There have been several studies aimed at finding drugs able to potentiate the antiproliferative effects of cisplatin without increasing the already serious side effects, but the search has not been successful.
In this work we investigated the ability of a progesterone antagonist, mifepristone, to modulate the cytotoxic effects of cisplatin in cancer cell lines and in a model of cervix cancer in athymic mice.
Materials and methods
The effect of cisplatin alone and cisplatin combined with mifepristone on cellular death was studied using an assay based on a tetrazolium dye, XTT. Before and after treatment with mifepristone, the intracellular accumulation of cisplatin in cancer cells and tumors of mice receiving treatment was evaluated by HPLC, the expression of Bcl-2 gene was assessed by RT-PCR and western blotting. Tumors measurements were performed weekly using vernier calipers.
Analysis of the data by the isobologram method shows that the combination of mifepristone and cisplatin produced a synergistic effect in cervical cancer cells. The effect of mifepristone on the cytotoxicity of cisplatin could be mediated, at least partially, by increase of intracellular cisplatin accumulation and the down-regulation of the Bcl-2 expression. The in vivo studies showed that the combination of these agents had a significant antitumor activity against xenograft tumors.
Our results suggest that mifepristone can improve the efficacy of cisplatin in cancer cells and this anti-hormonal drug therapy may be a candidate for further evaluation in combination with antineoplastic drugs in the treatment of cancer.
This work was support by the CONACYT (México) Grant No. P44176-M
This article is published under license to BioMed Central Ltd.